Memantine Receives Tentative FDA Nod, Says Wockhardt

by Rajshri on  January 7, 2010 at 9:36 PM Corporate News
RSS Email Print This Page Comment bookmark
Font : A-A+

 Memantine Receives Tentative FDA Nod, Says Wockhardt
Wockhardt Limited has announced that it has received tentative approval from the US Food and Drug Administration for marketing market Memantine tablets in the strength of 5 mg and 10 mg. Memantine is used in the treatment of Alzheimer`s disease.

The drug works by suppressing N-Methyl-D-Aspartate (NMDA) receptors, which are thought to be responsible for the deterioration of cholinergic cells in the brain.

On December 29, Wockhardt had revealed that its preferential issue would not exceed 1.6 billion convertible or non-convertible redeemable preference shares worth Rs 5 each.



Source: Medindia
RAS

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive